- Home
- ACHV vs AGEN Comparison
ACHV vs AGEN Comparison
Compare ACHV & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHV
- AGEN
- Stock Information
- Founded
- ACHV N/A
- AGEN 1994
- Country
- ACHV Canada
- AGEN United States
- Employees
- ACHV N/A
- AGEN N/A
- Industry
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACHV Health Care
- AGEN Health Care
- Exchange
- ACHV Nasdaq
- AGEN Nasdaq
- Market Cap
- ACHV 92.6M
- AGEN 96.2M
- IPO Year
- ACHV N/A
- AGEN 2000
- Fundamental
- Price
- ACHV $2.70
- AGEN $1.51
- Analyst Decision
- ACHV Strong Buy
- AGEN Buy
- Analyst Count
- ACHV 4
- AGEN 4
- Target Price
- ACHV $15.75
- AGEN $8.00
- AVG Volume (30 Days)
- ACHV 162.2K
- AGEN 484.8K
- Earning Date
- ACHV 03-11-2025
- AGEN 03-11-2025
- Dividend Yield
- ACHV N/A
- AGEN N/A
- EPS Growth
- ACHV N/A
- AGEN N/A
- EPS
- ACHV N/A
- AGEN N/A
- Revenue
- ACHV N/A
- AGEN $103,463,000.00
- Revenue This Year
- ACHV N/A
- AGEN $32.21
- Revenue Next Year
- ACHV N/A
- AGEN N/A
- P/E Ratio
- ACHV N/A
- AGEN N/A
- Revenue Growth
- ACHV N/A
- AGEN N/A
- 52 Week Low
- ACHV $2.51
- AGEN $1.44
- 52 Week High
- ACHV $5.59
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- ACHV 41.28
- AGEN 21.95
- Support Level
- ACHV $2.70
- AGEN $1.55
- Resistance Level
- ACHV $2.99
- AGEN $1.77
- Average True Range (ATR)
- ACHV 0.20
- AGEN 0.14
- MACD
- ACHV 0.01
- AGEN 0.02
- Stochastic Oscillator
- ACHV 34.55
- AGEN 9.85
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).